FLEX will include full transcriptome data paired with 800 data points from 10,000 patients, offering researchers the chance to study diverse patient subsets.
PathoNext will run Agendia's assays in its labs using next-generation sequencing and work with HiSS, Agendia's German distributor, to offer the tests to German patients.
Recently presented data confirm prior findings that Agendia's MammaPrint may help doctors decide whether to limit tamoxifen treatment in certain patients.
A retrospective cohort study uncovered microRNA signatures that could tell lung cancer patients apart from others, including patients with other, non-tumor lung conditions.
Tempus said that Akesogen's lab provides a range of testing services, including for inherited risk of cancer, microbiome profiling, whole-genome genotyping, and more.
In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.
